158 related articles for article (PubMed ID: 25270152)
1. Anti-B cell therapy with rituximab as induction therapy in renal transplantation.
Joosten I; Baas MC; Kamburova EG; van den Hoogen MW; Koenen HJ; Hilbrands LB
Transpl Immunol; 2014 Oct; 31(4):207-9. PubMed ID: 25270152
[TBL] [Abstract][Full Text] [Related]
2. Anti-T-cell antibodies for the treatment of acute rejection after renal transplantation.
van den Hoogen MW; Hoitsma AJ; Hilbrands LB
Expert Opin Biol Ther; 2012 Aug; 12(8):1031-42. PubMed ID: 22583145
[TBL] [Abstract][Full Text] [Related]
3. The effects of in vivo B-cell depleting therapy on ex-vivo cytokine production.
Smeekens SP; van den Hoogen MW; Kamburova EG; van de Veerdonk FL; Joosten I; Koenen HJ; Netea MG; Hilbrands LB; Joosten LA
Transpl Immunol; 2013 Jun; 28(4):183-8. PubMed ID: 23651756
[TBL] [Abstract][Full Text] [Related]
4. Rituximab as induction therapy after renal transplantation: a randomized, double-blind, placebo-controlled study of efficacy and safety.
van den Hoogen MW; Kamburova EG; Baas MC; Steenbergen EJ; Florquin S; M Koenen HJ; Joosten I; Hilbrands LB
Am J Transplant; 2015 Feb; 15(2):407-16. PubMed ID: 25612493
[TBL] [Abstract][Full Text] [Related]
5. BAFF may modulate the rate of B-cell repopulation after rituximab therapy for acute renal transplant rejection.
Zarkhin V; Li L; Sarwal MM
Transplantation; 2009 Nov; 88(10):1229-30. PubMed ID: 19935379
[No Abstract] [Full Text] [Related]
6. Discrepancy of B cell frequency between periphery and spleen after rituximab treatment in ABO-incompatible liver transplantation.
Iso Y; Sawada T; Kita J; Shiraki T; Sakuraoka Y; Kato M; Shimoda M; Kubota K
Hepatogastroenterology; 2013 Oct; 60(127):1624-6. PubMed ID: 24634932
[TBL] [Abstract][Full Text] [Related]
7. Rituximab in the treatment of acute cellular rejection of renal allograft with CD20-positive clusters in the infiltrate.
Vega J; Goecke H; Carrasco A; Escobar C; Escobar M; Espinosa R; Méndez G; de Los Ángeles Rodríguez M
Clin Exp Nephrol; 2011 Apr; 15(2):308-11. PubMed ID: 21152944
[TBL] [Abstract][Full Text] [Related]
8. Desensitization protocol for highly sensitized renal transplant patients: a single-center experience.
Kute VB; Vanikar AV; Trivedi HL; Shah PR; Goplani KR; Patel HV; Gumber MR; Patel RD; Kanodia KV; Suthar KS; Trivedi VB; Modi PR
Saudi J Kidney Dis Transpl; 2011 Jul; 22(4):662-9. PubMed ID: 21743208
[TBL] [Abstract][Full Text] [Related]
9. A randomized, prospective trial of rituximab for acute rejection in pediatric renal transplantation.
Zarkhin V; Li L; Kambham N; Sigdel T; Salvatierra O; Sarwal MM
Am J Transplant; 2008 Dec; 8(12):2607-17. PubMed ID: 18808404
[TBL] [Abstract][Full Text] [Related]
10. Differential modulation of donor-specific antibodies after B-cell depleting therapies to cure chronic antibody mediated rejection.
Touzot M; Couvrat-Desvergnes G; Castagnet S; Cesbron A; Renaudin K; Cantarovich D; Giral M
Transplantation; 2015 Jan; 99(1):63-8. PubMed ID: 25029384
[TBL] [Abstract][Full Text] [Related]
11. Recipient memory-like lymphocytes remain unresponsive to graft antigens after CAMPATH-1H induction with reduced maintenance immunosuppression.
Trzonkowski P; Zilvetti M; Friend P; Wood KJ
Transplantation; 2006 Nov; 82(10):1342-51. PubMed ID: 17130784
[TBL] [Abstract][Full Text] [Related]
12. B-cell-depleting induction therapy and acute cellular rejection.
Clatworthy MR; Watson CJ; Plotnek G; Bardsley V; Chaudhry AN; Bradley JA; Smith KG
N Engl J Med; 2009 Jun; 360(25):2683-5. PubMed ID: 19535812
[No Abstract] [Full Text] [Related]
13. Cytokine Release After Treatment With Rituximab in Renal Transplant Recipients.
Kamburova EG; van den Hoogen MW; Koenen HJ; Baas MC; Hilbrands LB; Joosten I
Transplantation; 2015 Sep; 99(9):1907-11. PubMed ID: 25675201
[TBL] [Abstract][Full Text] [Related]
14. Impact of rituximab therapy on response to tetanus toxoid vaccination in kidney-transplant patients.
Puissant-Lubrano B; Rostaing L; Kamar N; Abbal M; Fort M; Blancher A
Exp Clin Transplant; 2010 Mar; 8(1):19-28. PubMed ID: 20199367
[TBL] [Abstract][Full Text] [Related]
15. Lymphocyte subsets during and after rabbit anti-thymocyte globulin induction in pediatric renal transplantation: sustained T cell depletion.
Bell L; Girardin C; Sharma A; Goodyer P; Mazer B
Transplant Proc; 1997 Nov; 29(7A):6S-9S. PubMed ID: 9366917
[No Abstract] [Full Text] [Related]
16. Phenotypic evaluation of B-cell subsets after rituximab for treatment of acute renal allograft rejection in pediatric recipients.
Zarkhin V; Lovelace PA; Li L; Hsieh SC; Sarwal MM
Transplantation; 2011 May; 91(9):1010-8. PubMed ID: 21403590
[TBL] [Abstract][Full Text] [Related]
17. Rationale and design of the RIACT-study: a multi-center placebo controlled double blind study to test the efficacy of RItuximab in Acute Cellular tubulointerstitial rejection with B-cell infiltrates in renal Transplant patients: study protocol for a randomized controlled trial.
Schiffer L; Schiffer M; Merkel S; Schwarz A; Mengel M; Jürgens C; Schroeder C; Zoerner AA; Püllmann K; Bröcker V; Becker JU; Dämmrich ME; Träder J; Grosshennig A; Biertz F; Haller H; Koch A; Gwinner W
Trials; 2012 Oct; 13():199. PubMed ID: 23101480
[TBL] [Abstract][Full Text] [Related]
18. A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation.
Farney AC; Doares W; Rogers J; Singh R; Hartmann E; Hart L; Ashcraft E; Reeves-Daniels A; Gautreaux M; Iskandar SS; Moore P; Adams PL; Stratta RJ
Transplantation; 2009 Sep; 88(6):810-9. PubMed ID: 19920781
[TBL] [Abstract][Full Text] [Related]
19. Refractory acute kidney transplant rejection with CD20 graft infiltrates and successful therapy with rituximab.
Alausa M; Almagro U; Siddiqi N; Zuiderweg R; Medipalli R; Hariharan S
Clin Transplant; 2005 Feb; 19(1):137-40. PubMed ID: 15659147
[TBL] [Abstract][Full Text] [Related]
20. Rituximab in renal transplantation.
Barnett AN; Hadjianastassiou VG; Mamode N
Transpl Int; 2013 Jun; 26(6):563-75. PubMed ID: 23414100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
